Evidence map›Paper›PMID 39671301›Full record

ArticleThoracic cancer2025

Sodium-Glucose Cotransporter 2 Inhibitors for Mesenchymal-Epithelial Transition Inhibitor-Induced Edema.

Takuya Oyakawa, Keita Miura, Nao Muraoka, Kei Iida, Ayano Fujita, Tateaki Naito, Toshiaki Takahashi

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Thoracic cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Weight change and impact on prognosis in patients with advanced non-small cell lung cancer with concomitant diabetes mellitus treated with sglt2 inhibitors.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Takuya OyakawaDivision of Cardio-oncology, Shizuoka Cancer Center, Shizuoka, Japan.ORCID https://orcid.org/0000-0001-7637-5501
Keita MiuraDivision of Thoracic oncology, Shizuoka Cancer Center, Shizuoka, Japan.
Nao MuraokaDivision of Cardio-oncology, Shizuoka Cancer Center, Shizuoka, Japan.
Kei IidaDivision of Cardio-oncology, Shizuoka Cancer Center, Shizuoka, Japan.
Ayano FujitaDivision of Cardio-oncology, Shizuoka Cancer Center, Shizuoka, Japan.
Tateaki NaitoDivision of Thoracic oncology, Shizuoka Cancer Center, Shizuoka, Japan.ORCID https://orcid.org/0000-0003-4047-2929
Toshiaki TakahashiDivision of Thoracic oncology, Shizuoka Cancer Center, Shizuoka, Japan.ORCID https://orcid.org/0000-0002-8188-2505

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors on mesenchymal-epithelial transition factor (MET) inhibitor-induced edema remain unclear. In a patient with tepotinib-induced edema and an N-terminal pro-brain natriuretic peptide (NTproBNP) level ≥ 300 pg/mL, the addition of empagliflozin to loop diuretics reduced the edema. This suggests that empagliflozin may be a treatment option for MET inhibitor-induced edema.

Indexed as

EdemaEpithelial-Mesenchymal TransitionSodium-Glucose Transporter 2 InhibitorsBenzhydryl CompoundsFemaleGlucosidesHumansMaleBenzhydryl CompoundsempagliflozinGlucosidesSodium-Glucose Transporter 2 Inhibitorscardio‐oncologyedemalung cancerMETSGLT2 inhibitor

Identifiers

PMID39671301
PMCPMC11735732

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.